cladribine has been researched along with MS (Multiple Sclerosis) in 228 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (8.33) | 18.2507 |
| 2000's | 28 (12.28) | 29.6817 |
| 2010's | 47 (20.61) | 24.3611 |
| 2020's | 134 (58.77) | 2.80 |
| Authors | Studies |
|---|---|
| Avxentyev, NA; Davydovskaya, MV; Frolov, MY; Klabukova, DL; Makarova, YV | 1 |
| Battaglia, MA; Brichetto, G; Caleri, F; Callari, G; Carmisciano, L; Clerico, M; Cordera, S; Cordioli, C; Da Rin, G; Di Sapio, A; Ferrò, MT; Franciotta, D; Frau, J; Gandoglia, I; Gazzola, P; Inglese, M; Iodice, R; Landi, D; Lapucci, C; Laroni, A; Liberatore, G; Mannironi, A; Marinelli, F; Pasquali, L; Perego, G; Repice, AM; Salvetti, M; Schiavetti, I; Serrati, C; Signoriello, E; Sormani, MP; Stromillo, ML; Tassinari, T; Uccelli, A; Ulivelli, M | 1 |
| Adamec, I; Habek, M; Jovanović, I; Krbot Skorić, M | 1 |
| Fenwick, E; Harty, GT; Kroep, S; Piena, MA; Simons, C; van Hout, BA; Wong, SL | 1 |
| Akgün, K; Feige, J; Haschke-Becher, E; Hoepner, L; Moser, T; Schwenker, K; Seiberl, M; Sellner, J; Ziemssen, T | 1 |
| Brescia Morra, V; Capasso, N; Carotenuto, A; Cerbone, V; Covelli, B; Lanzillo, R; Moccia, M; Molinari, EA; Novarella, F; Petracca, M; Scalia, G; Spiezia, AL | 1 |
| Baker, D; Dobson, R; Giovannoni, G; Kang, AS; MacDougall, A; Schmierer, K | 1 |
| Battistini, L; Furlan, R; Moiola, L; Nicoletti, F; Riva, A; Salvetti, M; Uccelli, A | 1 |
| Aldridge, J; Coyle, PK; Galazka, A; Giovannoni, G; Leist, TP; Lemieux, C; Nolting, A; Vermersch, P; Walker, B | 1 |
| Brescia Morra, V; Carotenuto, A; Disanto, G; Gobbi, C; Moccia, M; Sacco, R; Spiezia, AL; Zecca, C | 1 |
| Aldridge, J; Dangond, F; Giovannoni, G; Jack, D; Lebson, LA; Leist, TP; Nolting, A; Oh, J; Walker, B | 1 |
| Aybar, F; Correale, J; Eugenia Samman, M; Julia Perez, M; María Pasquini, J; Marrodan, M; Silvina Marcora, M | 1 |
| Cola, G; Di Mauro, G; Grimaldi, A; Landi, D; Marfia, GA; Mataluni, G; Nicoletti, CG | 1 |
| Brill, L; Haham, N; Levin, N; Rechtman, A; Rozenberg, A; Shifrin, A; Vaknin-Dembinsky, A; Zveik, O | 1 |
| Alexandri, N; Brochet, B; Havrdova, EK; Hupperts, R; Keller, B; Langdon, D; Lechner-Scott, J; Montalban, X; Nolting, A; Patti, F; Piehl, F; Rejdak, K; Selmaj, K; Solari, A; Valis, M | 1 |
| Annovazzi, P; Brescia Morra, V; Buonomo, AR; Buscarinu, MC; Calabrese, M; Cavalla, P; Cocco, E; Cordioli, C; De Angelis, M; De Luca, G; Di Filippo, M; Ferraro, D; Gajofatto, A; Gasperini, C; Gentile, I; Lanzillo, R; Maniscalco, GT; Moccia, M; Nociti, V; Paolicelli, D; Petruzzo, M; Pinardi, F; Radaelli, M; Scotto, R; Solaro, C; Spiezia, AL; Tomassini, V; Viceconte, G; Zappulo, E | 1 |
| Lallas, A; Papadopoulou, A; Papazisis, G; Rigas, A; Stamatellos, VP; Stamoula, E | 1 |
| Bagatto, D; Battezzi, A; Deana, C; Lorenzut, S; Pecori, D; Tuniz, F | 1 |
| Aydemir, A; Bezemer, I; Butzkueven, H; Korhonen, P; Moore, N; Sabidó, M; Sõnajalg, J | 1 |
| Papazisis, G; Stamatellos, VP | 1 |
| Moser, T; Sellner, J; Ziemssen, T | 1 |
| Celius, EG; Høgestøl, EA; Myhr, KM; Nygaard, GO; Skattebøl, L; Sowa, P; Torgauten, H; Torkildsen, Ø | 1 |
| Atula, S; Järvinen, E; Kuusisto, H; Rauma, I; Ryytty, M; Sipilä, JOT; Soilu-Hänninen, M; Viitala, M | 1 |
| Burman, J; Bø, L; Kvistad, SAS; Lehmann, AK; Melve, GK; Tolf, A; Torkildsen, Ø; Zjukovskaja, C | 1 |
| Basu, S; Ben-Amor, AF; Girard, P; Munafo, A; Roy, S; Terranova, N | 1 |
| Chandran, S; Connick, P; Foley, P; Glasmacher, SA; Hassan, Z; Kearns, PK; Reetz, K; Tauber, S | 1 |
| Al-Harbi, T; Alroughani, R; Ampapa, R; Barnett, M; Bergamaschi, R; Bovis, F; Boz, C; Butler, E; Butzkueven, H; Buzzard, K; Cartechini, E; Castillo-Triviño, T; Cristiano, E; Csepany, T; de Gans, K; Dominguez, JA; Duquette, P; Eichau, S; Ferraro, D; Fragoso, Y; Gerlach, O; Girard, M; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Havrdova, EK; Hodgkinson, S; Horakova, D; Hughes, S; Iuliano, G; Izquierdo, G; Kalincik, T; Kappos, L; Kermode, A; Lechner-Scott, J; Lugaresi, A; Macdonell, R; Malpas, C; McCombe, P; Moore, F; Onofrj, M; Ozakbas, S; Petersen, T; Prat, A; Prevost, J; Rozsa, C; Saladino, ML; Sanchez-Menoyo, JL; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Shuey, N; Sidhom, Y; Simo, M; Singhal, B; Sirbu, CA; Skibina, O; Slee, M; Sola, P; Solaro, C; Sormani, MP; Soysal, A; Spitaleri, D; Taylor, B; Terzi, M; Trojano, M; Turkoglu, R; van der Walt, A; van Pesch, V; Van Wijmeersch, B; Vucic, S; Yamout, B | 1 |
| Afanasiev, S; Brill, L; Haham, N; Levin, N; Rechtman, A; Rozenberg, A; Shifrin, A; Vaknin-Dembinsky, A; Zveik, O | 1 |
| Boschert, U; Centonze, D; Chudecka, A; Oreja-Guevara, C; Roy, S; Schmierer, K; Wiendl, H | 2 |
| Abhari, AP; Baratian, M; Etemadifar, M; Idda, ML; Mahdavi, S; Nouri, H; Pitzalis, M; Salari, M; Sedaghat, N | 1 |
| Aslan, D; Hackert, J; Hagenacker, T; Huntemann, N; Kleinschnitz, C; Kleinschnitz, K; Meuth, SG; Pawlitzki, M; Pfeuffer, S; Pul, R; Rolfes, L; Ruck, T; Schmidt, M; Skuljec, J; Su, C | 1 |
| Achiron, A; Barkhof, F; Chan, A; de Stefano, N; Derfuss, T; Hodgkinson, S; Keller, B; Leocani, L; Montalban, X; Prat, A; Roy, S; Schmierer, K; Sellebjerg, F; Vermersch, P; Wiendl, H | 1 |
| Aprico, A; Ayoub, S; Binder, MD; Johnson, LJ; Kilpatrick, TJ; Medeiros-Furquim, T; Nwoke, E | 1 |
| Butler, E; Butzkueven, H; Buzzard, K; Eichau, S; Girard, M; Hodgkinson, S; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Monif, M; Oh, J; Prevost, J; Skibina, O; van der Walt, A; Van Pesch, V; Zhong, M | 1 |
| Boyko, AN | 1 |
| Damian, D; Dangond, F; Galazka, A; Harty, G; Jack, D; Vermersch, P; Wong, SL | 2 |
| Bayas, A; Kallmann, B; Kleinschnitz, C; Linker, R; Mäurer, M; Meuth, SG; Rieckmann, P; Wattjes, MP | 1 |
| Brod, SA | 1 |
| Comi, G; Dangond, F; Giovannoni, G; Jack, D; Rammohan, K; Rieckmann, P; Vermersch, P | 1 |
| Alexandri, N; Coyle, PK; Dangond, F; Galazka, A; Giovannoni, G; Leist, TP; Rammohan, K; Sormani, MP; Stefano, N | 1 |
| Albanese, A; Gattorno, G; Schiavetti, I; Sormani, MP | 1 |
| Fleifel, L; Khamis, C; Koussa, S; Matni, M; Mohamed, O; Sharifi, S; Yamout, B | 1 |
| Achiron, A; Didikin, M; Dreyer-Alster, S; Flechter, S; Harari, G; Magalashvili, D; Mandel, M | 1 |
| Alexandri, N; Battaglini, M; Cortese, R; De Stefano, N; Gentile, G; Inderyas, M; Luchetti, L; Sormani, MP | 1 |
| Brownlee, WJ | 2 |
| Agostoni, EC; Pirro, F; Protti, A; Saraceno, L; Stigliano, R | 1 |
| Haug, U; Kollhorst, B; Platzbecker, K; Wentzell, N | 1 |
| Alroughani, R; Barnett, M; Boz, C; Butzkueven, H; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Karabudak, R; Khoury, SJ; Kubala Havrdova, E; Kuhle, J; Lechner-Scott, J; Macdonell, R; Merlo, D; Monif, M; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Prevost, J; Roos, I; Skibina, O; Slee, M; van der Walt, A; Van Pesch, V; Zhou, Z; Zhu, C | 1 |
| Ciplea, AI; Dost-Kovalsky, K; Gold, R; Hellwig, K; Thiel, S | 1 |
| Bernasconi, E; Cantu', M; Disanto, G; Eisler, JJ; Galante, A; Gobbi, C; Keller, F; Mele, F; Sacco, R; Sallusto, F; Zecca, C | 1 |
| Achiron, A; Barkhof, F; Boschert, U; Chan, A; Chudecka, A; De Stefano, N; Derfuss, T; Hodgkinson, S; Holmberg, KH; Leocani, L; Montalban, X; Mwape, C; Prat, A; Roy, S; Schmierer, K; Sellebjerg, F; Vermersch, P; Wiendl, H | 1 |
| Homa, M; Kaczor, MP; Kaczyński, Ł; Paczwa, P; Piasecka-Stryczyńska, K; Rejdak, K; Rolka, M; Staśkiewicz, W; Wójcik, R | 1 |
| Al-Asmi, A; Alroughani, R; Altintas, A; Ampapa, R; Blanco Morgado, Y; Butzkueven, H; Gerlach, O; Hodgkinson, S; Horakova, D; Kalincik, T; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; Oh, J; Ozakbas, S; Patti, F; Sanchez-Menoyo, JL; Soysal, A; Spelman, T; Spitaleri, D; Terzi, M; Tundia, N; Van Der Walt, A; van Pesch, V; Wong, SL; Yamout, B | 1 |
| Aglas-Leitner, FT; Byrne, SN; Grau, GE; Hawke, S; Juillard, A; Juillard, P; Marsh-Wakefield, F | 1 |
| Andreone, V; Belardo, M; De Rosa, V; Di Battista, ME; Di Giulio Cesare, D; Ferrara, AL; Liotti, A; Longo, K; Maniscalco, GT; Moreggia, O; Napolitano, M; Prestipino, E; Ranieri, A; Salvatore, S; Vastano, R | 1 |
| Assefi, A; D'Eramo, M; Etchepare, A; Grinspan, A; Iut, VC; Negrotto, L | 1 |
| Brownlee, W; Celius, EG; Centonze, D; Giovannoni, G; Havrdova, EK; Hodgkinson, S; Kleinschnitz, C; Magyari, M; Oreja-Guevara, C; Salloukh, H; Selchen, D; Van Wijmeersch, B; Vermersch, P; Wiendl, H; Yamout, B | 1 |
| Heick, A; Joensen, H; Magyari, M; Pihl, CE; Pontieri, L; Rasmussen, PV; Ratzer, R; Schäfer, J; Sellebjerg, F; Sorensen, PS | 1 |
| Ginestal, R; Los Santos, H; Morán, OD; Ordoñez, C; Rubio-Rodríguez, D; Rubio-Terrés, C; Sánchez-Magro, I | 1 |
| Dang, YL; Kalincik, T; Perucca, P; Sharmin, S; Yong, VT | 1 |
| Buchmann, A; Feige, J; Harrer, A; Hilpold, P; Hitzl, W; Khalil, M; Machegger, L; Moser, T; Seiberl, M; Trinka, E; Wipfler, P | 1 |
| Apóstolos-Pereira, SL; Callegaro, D; Mahler, JV; Nascimento, RFV; Pipek, LZ; Silva, GD | 1 |
| Bakkioui, S; Brieva, L; Gil Sánchez, A; González-Mingot, C; Peralta, S; Quibus, L; Ruiz-Fernández, E; San Pedro-Murillo, E; Sancho-Saldaña, A; Solana, MJ; Torres, P | 1 |
| Gabernet, G; Jarboui, MA; Kemmerer, CL; Klose, F; Kowarik, MC; Nahnsen, S; Poli, S; Ruschil, C; Ziemann, U | 1 |
| Aydemir, A; Borsi, L; Boyko, A; Correale, J; Edan, G; Freedman, MS; Giovannoni, G; Leist, T; Montalban, X; Rammohan, K; Stefoski, D; Verdun di Cantogno, E; Yamout, B | 1 |
| Ferrè, L; Filippi, M; Martinelli, V; Meani, A; Moiola, L; Rocca, MA; Zanetta, C | 1 |
| Grau, GE; Hawke, S; Juillard, P; Lin, LY; Marsh-Wakefield, F | 1 |
| Afrashteh, F; Mirmosayyeb, O; Mohamadi, M; Nabizadeh, F; Najdaghi, S; Rahmani, S; Rajabi, R | 1 |
| Aslan, D; Hagenacker, T; He, X; Kleinschnitz, C; Kleinschnitz, K; Korsen, M; Meuth, SG; Oezalp, SH; Pawlitzki, M; Pfeuffer, S; Pul, R; Rolfes, L; Ruck, T; Skuljec, J; Su, C | 1 |
| Binko, TS; Cobanovic, S; Holm Hansen, R; Mahler, MR; Sellebjerg, F; von Essen, MR | 1 |
| Aerts, S; Khan, H; Peeters, LM; Popescu, V; Severijns, D; Van Wijmeersch, B | 1 |
| Boschert, U; Cerra, J; Giovannoni, G; Kalatskaya, I; Leist, T; Rolfe, PA | 1 |
| Akçin, R; Arslan, G; Baba, C; Beckmann, Y; Bilge, U; Boz, C; Bünül, SD; Demir, S; Dinç, Ö; Doğan, İG; Efendi, H; Elverdi, T; Gezen, O; Gümüş, H; Gündüz, T; Karabudak, R; Koç, R; Kocazeybek, B; Köseoğlu, M; Kürtüncü, M; Özakbaş, S; Özen, PA; Saip, S; Şen, S; Siva, A; Terzi, M; Tezer, DÇ; Tuncer, A; Turan, ÖF; Tütüncü, M; Uygunoğlu, U; Uzunköprü, C | 1 |
| Budimkic, MS; Drulovic, J; Ivanovic, J; Mesaros, S; Momcilovic, N | 1 |
| Al-Asmi, A; Alroughani, R; Altintas, A; Ampapa, R; Butzkueven, H; Der Walt, AV; Gerlach, O; Hodgkinson, S; Horakova, D; Kalincik, T; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; Morgado, YB; Oh, J; Ozakbas, S; Patti, F; Pesch, VV; Sanchez-Menoyo, JL; Soysal, A; Spelman, T; Spitaleri, D; Terzi, M; Tundia, N; Wong, SL; Yamout, B | 1 |
| Brownlee, WJ; Duncan, J; Haghikia, A; Harty, GT; Hayward, B; Kayaniyil, S; Khan, Z; Millar, S; Waser, N | 1 |
| Ahmed, SF; Al-Hashel, J; AlMojel, M; Alroughani, R | 1 |
| Adamczyk-Sowa, M; Bartosik-Psujek, H; Chorąży, M; Jamróz-Wiśniewska, A; Kurkowska-Jastrzębska, I; Kułakowska, A; Piasecka-Stryczyńska, K; Pogoda-Wesołowska, A; Puz, P; Rejdak, K; Stępień, A; Słowik, A; Tokarz-Kupczyk, E | 1 |
| Barete, S; Bielle, F; Guillaume-Jugnot, P; Maillart, E; Shor, N; Zavanone, C | 1 |
| Axelsson, M; Brandt, AF; Carlin, G; Gafvelin, G; Grönlund, H; Hessa, T; Högelin, KA; Khademi, M; Kockum, I; Lycke, J; Malmeström, C; Olsson, T; Piehl, F; Rabenstein, M; Thomas, OG | 1 |
| Bergmann, W; Boxberger, N; Dudesek, A; Engelmann, R; Fitzner, B; Hecker, M; Koczan, D; Ludwig-Portugall, I; Meister, S; Müller, M; Putscher, E; Schwartz, M; Winkelmann, A; Zettl, UK | 1 |
| Abičić, A; Adamec, I; Barun, B; Bašić Kes, V; Brecl Jakob, G; Cindrić, I; Drulović, J; Gabelić, T; Gomezelj, S; Gržinčić, T; Habek, M; Klivényi, P; Krbot Skorić, M; Lazibat, I; Mesaroš, Š; Pekmezović, T; Radulović, L; Rajda, C; Rimac, J | 1 |
| Borràs, E; Boschert, U; Calvo-Barreiro, L; Comabella, M; Costa-Frossard, L; Eixarch, H; Espejo, C; Ferrer, M; Fissolo, N; Montalban, X; Sabidó, E; Sanchez, A; Villar, LM | 1 |
| Boyko, AN; Dolgushin, MB; Karalkina, MA | 1 |
| Andrada, FC; Clauze, A; Cooper, JF; Hughes, RJ; Jacobson, S; Lieberman, PM; Lu, F; Messick, TE; Monaco, MCG; Ohayon, J; Patel, RJ; Soldan, SS; Su, C | 1 |
| Bloch, S; Golan, D; Lavi, I; Mazar, M; Spierer, R | 1 |
| Alonso, R; Burgos, M; Cabrera, M; Carnero Contentti, E; Casas, M; Cohen, L; Cristiano, E; Deri, N; Garcea, O; Hryb, J; Knorre, E; Lazaro, L; Leguizamon, F; Liguori, NF; Liwacki, S; Luetic, G; Mainella, C; Martinez, A; Menichini, M; Miguez, J; Nofal, P; Pablo, L; Pappolla, A; Patrucco, L; Pestchanker, C; Piedrabuena, R; Pita, C; Rojas, JI; Silva, B; Tizio, S; Tkachuk, V; Vrech, C; Zanga, G | 1 |
| Amin, A; Ashton, L; Brownlee, W; Herbert, A | 1 |
| Edan, G; Le Page, E | 1 |
| Müller, B; Rau, D; Übler, S | 1 |
| Song, Y; Sundar, M; Tundia, N; Wang, Y; Wong, SL; Yang, D | 1 |
| Alexandri, N; Brieva, L; Brochet, B; Hupperts, R; Keller, B; Kubala Havrdova, E; Langdon, D; Lechner-Scott, J; Maida, EM; Montalban, X; Nolting, A; Patti, F; Piehl, F; Selmaj, K; Smyk, A; Solari, A | 1 |
| Benedetti, MD; Capobussi, M; Castellini, G; Featherstone, R; Filippini, G; Frau, S; Gonzalez-Lorenzo, M; Lucenteforte, E; Perduca, V; Tramacere, I; Virgili, G | 1 |
| Bencsik, K; Biernacki, T; Sandi, D; Vécsei, L | 1 |
| Álvarez-Cermeño, JC; Estrada-Pérez, V; Fernández, O; García-Merino, JA; Izquierdo, G; Oreja-Guevara, C; Rodríguez-Antigüedad, A; Saiz, A | 1 |
| Rommer, PS; Sellner, J | 1 |
| Boyko, AN; Evdoshenko, EP; Khachanova, NV; Melnikov, MV; Rozenson, OL; Sivertseva, SA; Spirin, NN; Vasilyev, AV | 1 |
| Alfieri, G; Annunziata, M; Cerillo, I; Florio, C; Guarcello, G; Improta, G; Iorio, WD; Maniscalco, GT; Ranieri, A; Renna, R | 1 |
| Comi, G; Cook, S; Damian, D; Dangond, F; Galazka, A; Giovannoni, G; Leist, T; Montalban, X; Schick, R | 1 |
| Allen-Philbey, K; Baker, D; De Trane, S; Giovannoni, G; Mateo-Casas, M; Mathews, J; O'Toole, EA; Reyes, S; Schmierer, K; Yildiz, O | 1 |
| Amor, S; Baker, D; Giovannoni, G; Kang, AS; Schmierer, K | 1 |
| Elkjaer, ML; Hyrlov, KH; Illes, Z; Jørgensen, LØ; Pedersen, AE; Svenningsen, ÅF; Weber, AB | 1 |
| Barnett, MH; Butler, E; Butzkueven, H; Fabris, J; Hodgkinson, S; Jack, D; Kalincik, T; Lechner-Scott, J; Lizak, N; McCombe, PA; Parratt, J; Shaw, C; Shuey, N; Skibina, O; Slee, M; Vucic, S | 1 |
| Bayas, A; Kallmann, B; Kleinschnitz, C; Linker, R; Mäurer, M; Meuth, SG; Rieckmann, P | 1 |
| Celius, EG | 1 |
| Galazka, A; Jack, D; Nolting, A | 1 |
| Davydovskaya, MV; Kurguzova, DO; Luchinina, EV; Serebrova, SY; Shelekhova, TV; Zhuravleva, MV | 1 |
| Akgün, K; Feige, J; Haschke-Becher, E; Moser, T; Schwenker, K; Seiberl, M; Sellner, J; Ziemssen, T | 1 |
| Buttari, F; Centonze, D; De Vito, F; Ferese, R; Finardi, A; Furlan, R; Gambardella, S; Gilio, L; Marfia, GA; Matarese, G; Paolillo, A; Salvetti, M; Simonelli, I; Stampanoni Bassi, M; Storto, M; Uccelli, A; Visconti, A | 1 |
| Filippi, M; Moiola, L; Nozzolillo, A; Preziosa, P; Rocca, MA | 1 |
| Comi, G; Cook, S; Damian, D; Galazka, A; Giovannoni, G; Leist, T; Montalban, X; Nolting, A; Syed, S | 1 |
| Ahmad, B; Gummi, R; Walsh, RD | 1 |
| Harrer, A; Moser, T; Pilz, G; Radlberger, RF; Sakic, I; Wipfler, P | 1 |
| Bartosik-Psujek, H; Górecka, M; Kaczor, M; Kaczyński, Ł; Rolka, M; Wójcik, R; Zięba, P | 1 |
| Filippi, M; Gelibter, S; Moiola, L; Orrico, M | 1 |
| Bowen, JD; Cree, BAC; Damian, D; Dangond, F; Galazka, A; Grosso, M; Hartung, HP; Hughes, B; Hyvert, Y; Jones, DL; Leist, TP; Vermersch, P | 1 |
| Adlard, N; Cameron, C; Drudge, C; Häring, DA; Klotz, L; Samjoo, IA; Stoneman, D; Worthington, E; Zhao, M | 1 |
| Gold, R; Hoffmann, O | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Damian, D; Galazka, A; Jack, D; Nolting, A | 1 |
| Hackert, J; Kleinschnitz, C; Korsen, M; Meuth, SG; Pawlitzki, M; Pfeuffer, S; Pul, R; Rolfes, L; Ruck, T; Sondermann, W; Wiendl, H | 1 |
| Atkins, HL; Bose, G; Freedman, MS; Rush, C | 1 |
| Butzkueven, H; Monif, M; O'Brien, T; Stankovich, J; Voo, VTF | 1 |
| Alexandri, N; Coyle, PK; Dangond, F; De Stefano, N; Galazka, A; Giovannoni, G; Keller, B; Leist, T; Rammohan, K; Sormani, MP | 1 |
| Hackert, J; Kleinschnitz, C; Kleinschnitz, K; Klotz, L; Meuth, SG; Pfeuffer, S; Pul, R; Rolfes, L; Ruck, T; Wiendl, H | 1 |
| Azzolini, F; Bellantonio, P; Bruno, A; Buttari, F; Centonze, D; Dolcetti, E; Fantozzi, R | 1 |
| Callegari, I; Derfuss, T; Galli, E | 1 |
| Bigaut, K; Cohen, M; de Seze, J; Durand-Dubief, F; Lebrun-Frenay, C; Maillart, E; Planque, E; Zephir, H | 1 |
| Eisenberger, U; Fleischer, M; Gäckler, A; Hackert, J; Hagenacker, T; Kleinschnitz, C; Krämer, J; Kribben, A; Meuth, SG; Pfeuffer, S; Pfister, F; Pul, R; Ruck, T; Schönfelder, K; Schuh, H; Skuljec, J | 1 |
| Ethemoğlu, Ö; Seferoğlu, M; Siva, A; Turan, ÖF | 1 |
| Becker, V; Elias-Hamp, B; Grothe, C; Havla, J; Pul, R; Rau, D; Richter, S; Schmidt, S; Stangel, M | 1 |
| Comi, G; Dangond, F; Giovannoni, G; Jack, D; Keller, B; Rammohan, K; Rieckmann, P; Vermersch, P | 1 |
| Beiki, O; Clerico, M; Del Giovane, C; Filippini, G; Fredrikson, S; Mattoscio, M; Piazza, F; Salanti, G; Scalfari, A; Tramacere, I | 1 |
| Wiendl, H | 1 |
| Heesen, C; Riemann-Lorenz, K; Scheiderbauer, J; Schiffmann, I | 1 |
| De Stefano, N; Giorgio, A | 1 |
| Faissner, S; Gold, R | 1 |
| Aktas, O; Hartung, HP; Meuth, SG; Ruck, T | 1 |
| Rommer, PS; Zettl, UK | 1 |
| Ammoscato, F; Baker, D; Ceronie, B; Dubuisson, N; Giovannoni, G; Jacobs, BM; Lock, H; Longhurst, HJ; Mao, Z; Schmierer, K | 1 |
| Buc, M | 1 |
| Ammoscato, F; Baker, D; Giovannoni, G; Jacobs, BM; Schmierer, K | 1 |
| Mitsikostas, DD; Papadopoulos, D | 1 |
| Deeks, ED | 1 |
| Adams, A; Allen-Philbey, K; Álvarez-González, C; Baker, D; Campion, T; De Trane, S; Espasandin, M; Giovannoni, G; Gnanapavan, S; Mao, Z; Marta, M; Mathews, J; Schmierer, K; Turner, BP; Yildiz, O | 1 |
| Giovannoni, G; Hawkes, C; Lechner-Scott, J; Levy, M; Waubant, E | 1 |
| Alonso-Magdalena, L; Dangond, F; Galazka, A; Martinelli, V; Pfleger, C; Phillips, L; Rieckmann, P; Vermersch, P | 1 |
| Aschenbrenner, DS | 1 |
| Bénardais, K; Gudi, V; Prajeeth, CK; Singh, V; Stangel, M; Voss, EV | 1 |
| Berbecki, J; Dworzanska, E; Kolodziejczyk, B; Lobejko, K; Mitosek-Szewczyk, K; Nastaj, M; Rolinski, J; Stelmasiak, Z; Tabarkiewicz, J; Wilczynska, B | 1 |
| Casset-Semanaz, F; Comi, G; Coyle, PK; Cree, BA; Freedman, MS; Hartung, HP; Leist, TP; Scaramozza, M; Vermersch, P | 1 |
| Bourdette, D; Cameron, MH | 1 |
| Ekblom, M; Karlsson, MO; Munafo, A; Novakovic, AM; Savic, RM | 1 |
| Dwyer, MG; Filippi, M; Frohman, EM; Khan, O; Lassmann, H; Minagar, A; Racke, MK; Reder, AT; Stüve, O; Zivadinov, R | 1 |
| Borriello, G; Cefaro, LA; Gasperini, C; Pozzilli, C; Prosperini, L; Tosto, G | 1 |
| Dehmel, T; Döbert, M; Kieseier, BC; Kopadze, T; Leussink, VI | 1 |
| Hartung, HP; Kieseier, BC; Stüve, O; Wiendl, H | 1 |
| Gasperini, C; Ruggieri, S | 1 |
| Aktas, O; Giancarlo Comi, GC; Hartung, HP; Kieseier, B | 1 |
| Zéphir, H | 1 |
| Aktas, O; Hartung, HP; Kieseier, BC | 1 |
| Link, H; Martin, R | 1 |
| Hecht, B | 1 |
| Nau, JY | 1 |
| Banwell, B; Yiu, EM | 1 |
| Fontoura, P; Garren, H | 1 |
| Fox, EJ | 1 |
| Gold, R | 1 |
| Bonzano, L; De Stefano, N; Roccatagliata, L; Sormani, MP | 1 |
| Jadidi-Niaragh, F; Mirshafiey, A | 1 |
| Filippi, M | 1 |
| Carmona, O; Cocco, E; Drulovic, J; Duddy, M; Eggers, C; Gold, R; Haghikia, A; Zéphir, H | 1 |
| Goodin, D | 1 |
| Willoughby, E | 1 |
| Csépány, T | 1 |
| Aktas, O; Boyko, A; Goebels, N; Hartung, HP; Kieseier, BC; Leussink, VI; Warnke, C | 1 |
| Hohlfeld, R | 1 |
| Khachanova, NV | 1 |
| Borlat, F; Bruniquel, D; Chvatchko, Y; Galibert, L; Laugel, B; Vicari, A; Weissert, R | 1 |
| Graham-Rowe, D | 1 |
| Ais-Larisgoitia, A; de Lorenzo-Pinto, A; Rodríguez-González, CG | 1 |
| Comi, G; Cook, SD; Giovannoni, G; Greenberg, SJ; Hamlett, AC; Rammohan, K; Rieckmann, P; Sørensen, PS; Vermersch, P; Viglietta, V | 1 |
| Bandichhor, R; Iqbal, J; Mulakayala, N; Oruganti, S; Rao, P | 1 |
| Czerny, K; Kwietniewska, M; Sekita-Krzak, J; Stelmasiak, Z; Visconti, J | 2 |
| Cybulska, R; Czerny, K; Kwietniewska, M; Kwietniewski, P; Sekita-Krzak, J | 1 |
| Czerny, K; Kwietniewska, M | 1 |
| Sipe, JC | 1 |
| Cook, SD; Solanky, M; Van Engel, D; Wolansky, L | 1 |
| Brousil, JA; Roberts, RJ; Schlein, AL | 1 |
| Burton, JM; O'Connor, P | 1 |
| Gonsette, RE | 1 |
| Leist, TP; Vermersch, P | 1 |
| Barbuzzi, T; Brambilla, L; Castiglioni, C; Paci, M; Trivieri, G; Van Axel Castelli, V; Zanol, M; Zerbi, G; Zucchelli, I | 1 |
| Robak, E; Robak, T; Wierzbowska, A | 1 |
| Hartung, HP; Weilbach, FX | 1 |
| Beutler, E; Koziol, JA; McMillan, R; Romine, JS; Sipe, JC; Zyroff, J | 3 |
| Reilly, D | 1 |
| Koetsier, JC; Polman, CH | 1 |
| Grieb, P; Jakubowska, B; Nowicki, J; Ryba, M; Solski, J; Stelmasiak, Z | 2 |
| Beutler, E; Carrera, CJ; Koziol, JA; McMillan, R; Romine, JS; Sipe, JC | 1 |
| Becker, CC; Fleming, JO; Gidal, BE | 1 |
| Beutler, E; Koziol, J; McMillan, R; Romine, J; Sipe, J; Zyroff, J | 1 |
| Bekiesińska-Figatowska, M; Stelmasiak, Z; Walecki, J | 1 |
| Beutler, E; Frutos, A; Koziol, JA; Romine, JS; Sipe, JC | 1 |
| Schmied, M; Vass, K | 1 |
| Brandwein, J; O'Connor, P; Selby, R | 1 |
| Goodin, DS | 1 |
| Adams, HP; Beutler, E; Koziol, JA; Romine, JS; Sipe, JC; Slivka, LS; Sobel, DF; Wagner, S | 1 |
| Berger, T; Hilbe, W; Konwalinka, G; Thaler, J | 1 |
| Beutler, E; Koziol, JA; Lucero, A; Romine, JS; Sipe, JC | 1 |
| Comi, G; Filippi, M; Rice, GP | 1 |
| Bryant, J; Clegg, A; Milne, R | 1 |
| Donoghue, S; Greenlees, C | 1 |
| Comi, G; Filippi, M; Iannucci, G; Mennea, S; Rovaris, M; Sormani, MP | 1 |
| Bryant, J; Clegg, A | 1 |
| Brück, W; Lucchinetti, C; Noseworthy, J | 1 |
| Losy, J; Mehta, PD; Niezgoda, A | 1 |
| Chrapusta, SJ; Grieb, P; Hoser, G; Janisz, M; Kamienowski, J; Kawiak, J; Kuśnierczyk, P | 1 |
| Filippi, M; Rovaris, M; Tortorella, C | 1 |
| Myers, LW | 1 |
71 review(s) available for cladribine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
Topics: Cladribine; Humans; Immunosuppressive Agents; Language; Multiple Sclerosis; Tablets | 2022 |
Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).
Topics: Cladribine; Glatiramer Acetate; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2023 |
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.
Topics: Cladribine; COVID-19; COVID-19 Vaccines; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nucleosides; SARS-CoV-2; Tablets | 2022 |
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis.
Topics: Cladribine; COVID-19; COVID-19 Vaccines; Humans; Immunologic Factors; Multiple Sclerosis | 2022 |
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
Topics: Cladribine; Humans; Immunosuppressive Agents; Language; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2022 |
The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica.
Topics: Alemtuzumab; Antineoplastic Agents, Immunological; Cladribine; Humans; Immune Reconstitution; Multiple Sclerosis; Neuromyelitis Optica | 2022 |
Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
Topics: Cladribine; Humans; Immunosuppressive Agents; Language; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2022 |
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Topics: Cladribine; Humans; Immunosuppressive Agents; Language; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2022 |
COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis.
Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Multiple Sclerosis; Pandemics | 2022 |
Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
Topics: Bayes Theorem; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Network Meta-Analysis; Retrospective Studies; Tablets | 2022 |
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.
Topics: Chickenpox; Cladribine; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Influenza Vaccines; Influenza, Human; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2023 |
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence.
Topics: Cladribine; Expert Testimony; Humans; Immunosuppressive Agents; Lymphocytes; Multiple Sclerosis; Recurrence; Tablets | 2023 |
Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis.
Topics: Anticonvulsants; Bayes Theorem; Cladribine; Humans; Multiple Sclerosis; Network Meta-Analysis; Seizures | 2023 |
Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis.
Topics: Adult; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2023 |
Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.
Topics: Cladribine; Clinical Trials as Topic; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Observational Studies as Topic | 2023 |
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Registries; Tablets | 2023 |
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Topics: Adolescent; Adult; Alemtuzumab; Azathioprine; Cladribine; Daclizumab; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Immunotherapy; Interferon beta-1a; Interferon beta-1b; Male; Multiple Sclerosis; Natalizumab; Network Meta-Analysis; Rituximab; Young Adult | 2023 |
Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine.
Topics: Chemistry, Pharmaceutical; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Tablets | 2020 |
[Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Practice Guidelines as Topic; Recurrence; Tablets; Treatment Outcome | 2019 |
Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
Topics: Alemtuzumab; Autografts; Cladribine; Hematopoietic Stem Cell Transplantation; Humans; Immune Reconstitution; Multiple Sclerosis; Quality of Life | 2020 |
[New directions of immunocorrection in multiple sclerosis].
Topics: Alemtuzumab; Cladribine; Disease Progression; Humans; Multiple Sclerosis | 2020 |
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Betacoronavirus; CD8-Positive T-Lymphocytes; Cladribine; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Deprescriptions; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immune Evasion; Immunity, Innate; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lymphopenia; Macrophages; Monocytes; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Toluidines | 2020 |
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Drug Administration Schedule; Drug Monitoring; Expert Testimony; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Practice Guidelines as Topic; Recurrence; Tablets; Treatment Outcome | 2020 |
[Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis].
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2020 |
Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Network Meta-Analysis; Tablets | 2021 |
Efficacy classification of modern therapies in multiple sclerosis.
Topics: Cladribine; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Network Meta-Analysis; Recurrence | 2021 |
[Disease-modifying treatment of secondary progressive multiple sclerosis].
Topics: Cladribine; Disease Progression; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2021 |
The development and impact of cladribine on lymphoid and myeloid cells in multiple sclerosis.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Myeloid Cells | 2021 |
Update on treatment in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Algorithms; Antibodies, Monoclonal, Humanized; Cladribine; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Indans; Interferon-beta; Male; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Oxadiazoles; Pregnancy; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Toluidines | 2021 |
Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice.
Topics: Cladribine; Expert Testimony; Female; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neurologists; Pregnancy; Tablets | 2021 |
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Topics: Adjuvants, Immunologic; Cladribine; Cohort Studies; Crotonates; Disease Progression; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon beta-1a; Multiple Sclerosis; Nitriles; Publication Bias; Randomized Controlled Trials as Topic; Recurrence; Time Factors; Toluidines | 2017 |
Oral Therapies for Multiple Sclerosis.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Quinolones; Sphingosine 1 Phosphate Receptor Modulators; Toluidines | 2019 |
[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
Topics: Administration, Oral; Cladribine; Humans; Immunosuppressive Agents; Immunotherapy; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2018 |
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
Topics: Alemtuzumab; Cladribine; Crotonates; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Neoplasms; Nitriles; Toluidines | 2018 |
New biological agents in the treatment of multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cladribine; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Indans; Multiple Sclerosis; Natalizumab; Neuromyelitis Optica; Oxadiazoles; Rituximab | 2018 |
Cladribine: mechanisms and mysteries in multiple sclerosis.
Topics: Animals; Cladribine; Humans; Immunomodulation; Immunosuppressive Agents; Lymphocyte Subsets; Multiple Sclerosis | 2018 |
Cladribine Tablets: A Review in Relapsing MS.
Topics: Cladribine; Drug Interactions; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Tablets | 2018 |
Cladribine (Mavenclad) for multiple sclerosis.
Topics: Adult; Cladribine; Drug Costs; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Randomized Controlled Trials as Topic | 2019 |
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis.
Topics: Adrenal Cortex Hormones; Alemtuzumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Atrophy; Brain; Cladribine; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Interferon-beta; Multiple Sclerosis; Natalizumab; Organ Size; Peptides | 2008 |
Emerging oral drugs for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2008 |
New oral drugs for multiple sclerosis.
Topics: Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
Development of oral cladribine for the treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Cladribine; Clinical Trials as Topic; Drug Design; Humans; Immunosuppressive Agents; Multiple Sclerosis | 2010 |
[Cladribin. Development of an oral formulation for the treatment of multiple sclerosis].
Topics: Administration, Oral; Cladribine; Double-Blind Method; Humans; Immunosuppressive Agents; Infusions, Intravenous; Multiple Sclerosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
[Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
Topics: Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2010 |
Multiple sclerosis therapies: molecular mechanisms and future.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Crotonates; Daclizumab; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Mice; Multiple Sclerosis; Myelin Basic Protein; Nitriles; Peptide Fragments; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Vaccines, DNA | 2010 |
Emerging oral agents for multiple sclerosis.
Topics: 4-Aminopyridine; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Quinolones; Sphingosine | 2010 |
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Topics: Administration, Oral; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
Topics: Administration, Oral; Brain; Cladribine; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Predictive Value of Tests; Propylene Glycols; Recurrence; Regression Analysis; Reproducibility of Results; Sphingosine; Time Factors; Treatment Outcome | 2011 |
Therapeutic approach to multiple sclerosis by novel oral drug.
Topics: Administration, Oral; Cladribine; Crotonates; Diterpenes; Epoxy Compounds; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Patents as Topic; Phenanthrenes; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.
Topics: Biomarkers; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2011 |
Managing MS in a changing treatment landscape.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2011 |
[Current treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Dimethyl Fumarate; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quinolones; Sphingosine; Treatment Outcome | 2011 |
Cladribine as a therapeutic option in multiple sclerosis.
Topics: Cladribine; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Multiple Sclerosis | 2012 |
[Emerging therapies for multiple sclerosis].
Topics: 4-Aminopyridine; Administration, Oral; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Cladribine; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Young Adult | 2013 |
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
Topics: Cladribine; Crotonates; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Molecular Structure; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Small Molecule Libraries; Sphingosine; Toluidines | 2013 |
Cladribine for multiple sclerosis: review and current status.
Topics: Cladribine; Drug Interactions; Expert Testimony; Humans; Immunosuppressive Agents; Meta-Analysis as Topic; Multiple Sclerosis; Product Surveillance, Postmarketing | 2005 |
Aggressive central nervous system demyelination in an adolescent.
Topics: Adolescent; Cladribine; Demyelinating Diseases; Diagnosis, Differential; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Severity of Illness Index | 2005 |
Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
Topics: Cladribine; Drugs, Investigational; Humans; Multiple Sclerosis | 2006 |
Novel oral agents for multiple sclerosis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Isoxazoles; Leflunomide; Minocycline; Multiple Sclerosis; Mycophenolic Acid; Propylene Glycols; Pyridones; Quinolones; Sphingosine | 2007 |
Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
Topics: Antibodies, Monoclonal; Cladribine; Cyclophosphamide; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Isoxazoles; Ligands; Mitoxantrone; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
Topics: Administration, Oral; Cladribine; Humans; Multiple Sclerosis; Tablets | 2007 |
Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders.
Topics: Antineoplastic Agents; Autoimmune Diseases; Cladribine; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple Sclerosis; Treatment Outcome | 2006 |
Immunotherapy in multiple sclerosis, Part 2.
Topics: Adult; Azathioprine; Cladribine; Clinical Trials as Topic; Cyclophosphamide; Cyclosporins; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Immunotherapy; Interferons; Multiple Sclerosis; Peptides; Randomized Controlled Trials as Topic; Time Factors | 1995 |
[Current therapy of multiple sclerosis].
Topics: Azathioprine; Cladribine; Cyclophosphamide; Glatiramer Acetate; Humans; Interferon-beta; Methotrexate; Mitoxantrone; Multiple Sclerosis; Peptides; Plasmapheresis; Randomized Controlled Trials as Topic | 1996 |
Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis.
Topics: Cladribine; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Optic Neuritis; Research Design | 1999 |
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Topics: Adjuvants, Immunologic; Azathioprine; Cladribine; Cost-Benefit Analysis; Cyclophosphamide; Drug Costs; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-beta; Methotrexate; Mitoxantrone; Multiple Sclerosis; Peptides; Research Design; Technology Assessment, Biomedical; Treatment Outcome | 2000 |
Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies--an update.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Cladribine; Clinical Trials as Topic; Drugs, Investigational; Humans; Immunoglobulins, Intravenous; Interferon beta-1a; Interferon-beta; Mitoxantrone; Multiple Sclerosis | 2000 |
Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.
Topics: Azathioprine; Cladribine; Cost-Benefit Analysis; Cyclophosphamide; Drug Costs; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-beta; Methotrexate; Mitoxantrone; Multiple Sclerosis; Peptides | 2001 |
Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment.
Topics: Axons; Brain; Cladribine; Glatiramer Acetate; Humans; Immunization, Passive; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis; Oligodendroglia; Peptides | 2001 |
Cladribine. Ortho Biotech Inc.
Topics: Adenosine Deaminase Inhibitors; Animals; Antineoplastic Agents; Arthritis, Rheumatoid; Cladribine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Leukemia; Multiple Sclerosis; Structure-Activity Relationship | 2001 |
Immunologic therapy for secondary and primary progressive multiple sclerosis.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antilymphocyte Serum; Autoimmune Diseases; Cladribine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Forecasting; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Multiple Sclerosis; Peptides; Plasma Exchange; Randomized Controlled Trials as Topic; Steroids; T-Lymphocytes; Treatment Outcome; Vaccination | 2001 |
22 trial(s) available for cladribine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Topics: Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Quality of Life; Tablets | 2022 |
Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets.
Topics: Atrophy; Brain; Cladribine; Disease Progression; Gray Matter; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2023 |
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies | 2022 |
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2021 |
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Topics: Administration, Oral; Adolescent; Adult; Cladribine; Demyelinating Diseases; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Time Factors; Treatment Outcome; Young Adult | 2014 |
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis.
Topics: Adenine; Administration, Intravenous; Administration, Oral; Adult; Aged; Cladribine; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Biological; Multiple Sclerosis | 2017 |
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Topics: Analysis of Variance; Brain; Cladribine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Secondary Prevention; Severity of Illness Index; Tablets; Treatment Outcome | 2013 |
[Cladribine in chronic progressive multiple sclerosis].
Topics: Cladribine; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Infusion Pumps, Implantable; Multiple Sclerosis; Neurologic Examination | 1995 |
Cladribine in treatment of chronic progressive multiple sclerosis.
Topics: Adult; Brain; Cerebrospinal Fluid Proteins; Cladribine; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Neurologic Examination | 1994 |
Cladribine treatment of multiple sclerosis.
Topics: Cladribine; Humans; Multiple Sclerosis | 1994 |
Marrow suppression produced by repeated doses of cladribine.
Topics: Adult; Blood Cell Count; Bone Marrow; Chronic Disease; Cladribine; Depression, Chemical; Double-Blind Method; Female; Humans; Infusion Pumps, Implantable; Male; Multiple Sclerosis; Time Factors | 1994 |
The treatment of chronic progressive multiple sclerosis with cladribine.
Topics: Adult; Cladribine; Cross-Over Studies; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocyte Subsets; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Severity of Illness Index; Treatment Outcome | 1996 |
Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
Topics: Analysis of Variance; Autoimmune Diseases; Cladribine; Cross-Over Studies; Double-Blind Method; Follow-Up Studies; Hematologic Tests; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Neurologic Examination; Purpura, Thrombocytopenic, Idiopathic | 1996 |
The value of magnetic resonance imaging in diagnosis and monitoring of treatment in multiple sclerosis.
Topics: Adolescent; Adult; Aged; Child; Cladribine; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis | 1996 |
Development of cladribine treatment in multiple sclerosis.
Topics: Cladribine; Cross-Over Studies; Disease Progression; Double-Blind Method; Humans; Immunosuppressive Agents; Multiple Sclerosis | 1996 |
Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chronic Disease; Cladribine; Disability Evaluation; Disease Progression; Female; Humans; Immunosuppressive Agents; Injections, Subcutaneous; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Safety; Treatment Outcome | 1998 |
Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
Topics: Adult; Cladribine; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Neurologic Examination; Placebos; Treatment Outcome | 1999 |
Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial.
Topics: Cladribine; Cross-Over Studies; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neurologic Examination; Neuropsychological Tests; Treatment Outcome | 1999 |
Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.
Topics: Adult; Cladribine; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis | 2000 |
Whole brain volume changes in patients with progressive MS treated with cladribine.
Topics: Brain; Cladribine; Double-Blind Method; Humans; Magnetic Resonance Imaging; Multiple Sclerosis | 2000 |
Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis.
Topics: Adult; beta 2-Microglobulin; Cladribine; Female; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Male; Middle Aged; Multiple Sclerosis; Solubility | 2001 |
Hematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: a comparison of 2 dosage patterns.
Topics: Adult; Blood Cell Count; Cladribine; Drug Administration Schedule; Female; Humans; Lymphocyte Subsets; Male; Middle Aged; Multiple Sclerosis | 2001 |
135 other study(ies) available for cladribine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
[Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].
Topics: Adult; Cladribine; Economics, Pharmaceutical; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2021 |
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Topics: 2019-nCoV Vaccine mRNA-1273; Adult; Antibodies, Monoclonal, Humanized; Antibody Formation; BNT162 Vaccine; Cladribine; COVID-19; COVID-19 Vaccines; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Male; Middle Aged; Multiple Sclerosis; Prospective Studies; Rituximab; Treatment Outcome | 2021 |
Double immune reconstitution therapy: Cladribine after alemtuzumab in the treatment of multiple sclerosis.
Topics: Alemtuzumab; Cladribine; Humans; Immune Reconstitution; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing-Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach.
Topics: Cladribine; Cost-Benefit Analysis; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life | 2022 |
Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis.
Topics: Adult; B-Lymphocytes; Case-Control Studies; Cell Adhesion Molecules; Cladribine; Cytotoxicity, Immunologic; Female; Humans; Lymphocyte Subsets; Male; Middle Aged; Multiple Sclerosis; T-Lymphocytes; Young Adult | 2021 |
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis.
Topics: Cladribine; Humans; Immunoglobulins; Lymphocytes; Multiple Sclerosis; Neutrophils | 2022 |
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Cladribine; COVID-19; COVID-19 Vaccines; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2; Vaccination | 2022 |
Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets.
Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Influenza, Human; Multiple Sclerosis; SARS-CoV-2; Tablets; Vaccination | 2022 |
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
Topics: Adolescent; Adult; Age Factors; Aged; Cladribine; Humans; Infections; Lymphocyte Count; Lymphopenia; Middle Aged; Multiple Sclerosis; Tablets; Young Adult | 2021 |
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years.
Topics: Aged; Cladribine; Female; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Risk Assessment | 2022 |
2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells.
Topics: Apoptosis; Cladribine; Humans; Microglia; Multiple Sclerosis; Phosphorylation | 2022 |
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus.
Topics: Cladribine; COVID-19; Hepatitis B; Hepatitis B virus; Humans; Multiple Sclerosis; SARS-CoV-2 | 2022 |
Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis.
Topics: Antibodies, Viral; BNT162 Vaccine; Cladribine; COVID-19; COVID-19 Vaccines; Humans; mRNA Vaccines; Multiple Sclerosis; Pandemics; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, Synthetic | 2022 |
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
Topics: Antiviral Agents; Cladribine; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Middle Aged; Multiple Sclerosis; Retrospective Studies; Rituximab; Virus Activation | 2022 |
S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Skin Neoplasms; Sphingosine 1 Phosphate Receptor Modulators | 2022 |
Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nocardia Infections | 2022 |
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
Topics: Cladribine; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Registries; Tablets | 2022 |
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Rituximab | 2022 |
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
Topics: Adult; Cladribine; Cohort Studies; Fingolimod Hydrochloride; Finland; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Tablets | 2022 |
Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT.
Topics: Alemtuzumab; Cladribine; Hematopoietic Stem Cell Transplantation; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Rituximab; Transplantation, Autologous | 2022 |
Predicting disease activity in patients with multiple sclerosis: An explainable machine-learning approach in the Mavenclad trials.
Topics: Cladribine; Humans; Immunosuppressive Agents; Machine Learning; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2022 |
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis.
Topics: Adult; Cladribine; Cohort Studies; Disabled Persons; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Motor Disorders; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Topics: Cladribine; Cohort Studies; Disability Evaluation; Disease Progression; Female; Humans; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic | 2022 |
Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine.
Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Humans; Immunoglobulin G; Immunosuppressive Agents; mRNA Vaccines; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2; Tablets; Vaccines, Synthetic | 2022 |
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
Topics: Cladribine; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Influenza Vaccines; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2022 |
Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Topics: CD8-Positive T-Lymphocytes; Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recurrence | 2022 |
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
Topics: Adult; Cladribine; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Tablets | 2022 |
Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration
Topics: Biomarkers; Cladribine; Humans; Macrophage Activation; Macrophage Colony-Stimulating Factor; Monocytes; Multiple Sclerosis | 2022 |
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Topics: Chronic Disease; Cladribine; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
[Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].
Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2022 |
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2022 |
Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon.
Topics: Cladribine; Cost-Benefit Analysis; Humans; Immunosuppressive Agents; Lebanon; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2022 |
Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4.
Topics: Adult; Cladribine; Female; Humans; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome | 2022 |
Cladribine-induced liver injury: Implications for practice.
Topics: Chemical and Drug Induced Liver Injury, Chronic; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders.
Topics: Adult; Chemical and Drug Induced Liver Injury; Cladribine; Female; Humans; Immunosuppressive Agents; Multiple Sclerosis; Young Adult | 2022 |
Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany.
Topics: Child; Cladribine; Cross-Sectional Studies; Drug Utilization; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Infant, Newborn; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy | 2022 |
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Topics: Cladribine; Cohort Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome; Withholding Treatment | 2022 |
Cladribine and pregnancy in women with multiple sclerosis: The first cohort study.
Topics: Cladribine; Cohort Studies; Female; Humans; Immunosuppressive Agents; Infant, Newborn; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Outcome; Recurrence | 2023 |
Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year.
Topics: Antigens, CD20; Cladribine; COVID-19; Humans; Immunoglobulin G; Leukocytes, Mononuclear; Multiple Sclerosis; Prospective Studies; RNA, Messenger; SARS-CoV-2 | 2023 |
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy.
Topics: Antigens, CD19; Antigens, CD20; CD8-Positive T-Lymphocytes; Cladribine; Humans; Immunoglobulin G; Immunoglobulin M; Leukocytes, Mononuclear; Multiple Sclerosis; Tablets | 2023 |
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Retrospective Studies; Tablets | 2023 |
Mass cytometry reveals cladribine-induced resets among innate lymphoid cells in multiple sclerosis.
Topics: Cladribine; Humans; Immunity, Innate; Killer Cells, Natural; Leukocytes, Mononuclear; Multiple Sclerosis | 2022 |
Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Topics: Antibodies, Viral; BNT162 Vaccine; Cladribine; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Humans; Interferon beta-1a; Multiple Sclerosis; Prospective Studies; SARS-CoV-2; Vaccination | 2022 |
High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
Topics: Adult; Argentina; Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2022 |
Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Topics: Adult; Cladribine; Denmark; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2023 |
Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain.
Topics: Cladribine; Cost-Benefit Analysis; Dimethyl Fumarate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Spain | 2023 |
Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.
Topics: Biomarkers; Cladribine; Humans; Intermediate Filaments; Multiple Sclerosis; Neurofilament Proteins; Prospective Studies; Recurrence | 2023 |
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Cellular; Multiple Sclerosis; Natalizumab; Prospective Studies; SARS-CoV-2; Vaccination | 2023 |
Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients.
Topics: Cladribine; Clone Cells; Humans; Immunoglobulin Heavy Chains; Memory B Cells; Multiple Sclerosis; Proteome | 2023 |
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Topics: Cladribine; Follow-Up Studies; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Tablets | 2023 |
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
Topics: Cladribine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2023 |
Oral Cladribine Impairs Intermediate, but Not Conventional, Monocyte Transmigration in Multiple Sclerosis Patients across a Model Blood-Brain Barrier.
Topics: Blood-Brain Barrier; Cladribine; Humans; Leukocytes, Mononuclear; Monocytes; Multiple Sclerosis | 2023 |
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine.
Topics: Antibody Formation; Cladribine; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Multiple Sclerosis; Seasons; Vaccination | 2023 |
Cladribine Effects on T and B Cells and T Cell Reactivity in Multiple Sclerosis.
Topics: Cladribine; Cross-Sectional Studies; Guanine Nucleotide Exchange Factors; Humans; Immunosuppressive Agents; Multiple Sclerosis; T-Lymphocytes | 2023 |
Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
Topics: Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Tablets | 2023 |
Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment.
Topics: Algorithms; CD8-Positive T-Lymphocytes; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2023 |
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Female; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Prospective Studies; RNA, Messenger; SARS-CoV-2; Vaccination | 2023 |
Eyebrow alopecia associated with cladribine treatment for multiple sclerosis.
Topics: Alopecia; Cladribine; Eyebrows; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Tablets | 2023 |
A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine.
Topics: Adult; Cladribine; Contrast Media; Female; Follow-Up Studies; Gadolinium; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies | 2023 |
Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Topics: Adult; Cladribine; Cohort Studies; COVID-19; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Poland; Retrospective Studies; Tablets | 2023 |
Atypical multiple sclerosis associated with indolent systemic mastocytosis treated by cladribine.
Topics: Cladribine; Humans; Immunosuppressive Agents; Mastocytosis, Systemic; Multiple Sclerosis | 2023 |
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Topics: Adaptive Immunity; Alemtuzumab; Antibodies; Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Interferon-gamma; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Vaccination | 2023 |
Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.
Topics: Alemtuzumab; Cladribine; Humans; Immune Reconstitution; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neurodegenerative Diseases; RNA-Binding Proteins; Transcriptome; Ubiquitin-Protein Ligases | 2023 |
Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Retrospective Studies; Tablets | 2023 |
Molecular signature associated with cladribine treatment in patients with multiple sclerosis.
Topics: Biomarkers; Cladribine; Humans; Leukocytes, Mononuclear; MicroRNAs; Multiple Sclerosis; Proteomics | 2023 |
[New neuroimaging methods in assessing the activity of neuroinflammation in multiple sclerosis].
Topics: Brain; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neuroimaging; Neuroinflammatory Diseases; Tablets | 2023 |
EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls.
Topics: Case-Control Studies; Cell Line; Cell Proliferation; Cladribine; Epstein-Barr Virus Infections; Epstein-Barr Virus Nuclear Antigens; Herpesvirus 4, Human; Humans; Multiple Sclerosis | 2023 |
Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
Topics: Adult; Cladribine; COVID-19; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Sphingosine-1-Phosphate Receptors; Vaccination | 2023 |
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina.
Topics: Alemtuzumab; Argentina; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies | 2023 |
Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
Topics: Cladribine; England; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2023 |
Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
Topics: Alemtuzumab; Cladribine; Humans; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2023 |
Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
Topics: Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Patient Reported Outcome Measures; Prospective Studies; Tablets | 2023 |
Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
Topics: Adrenal Cortex Hormones; Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets; United States | 2023 |
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Topics: Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Tablets | 2023 |
Remission of early persistent cladribine-induced neutropenia after filgrastim therapy in a patient with Relapsing - Remitting Multiple Sclerosis.
Topics: Cladribine; Filgrastim; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neutropenia; Recombinant Proteins | 2020 |
Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Cladribine; Cohort Studies; Female; Humans; Immunosuppressive Agents; Male; Meta-Analysis as Topic; Multiple Sclerosis; Pregnancy; Pregnancy Outcome; Registries; Young Adult | 2020 |
Severe skin reactions associated with cladribine in people with multiple sclerosis.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neoplasms; Recurrence | 2020 |
Cladribine modifies functional properties of microglia.
Topics: Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Cell Movement; Cells, Cultured; Cladribine; Gene Expression Regulation; Humans; Lymphocyte Depletion; Mice; Mice, Inbred C57BL; Microglia; Multiple Sclerosis; Phagocytosis; Receptors, Tumor Necrosis Factor, Type II | 2020 |
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
Topics: Australia; Cladribine; Cohort Studies; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Registries | 2021 |
COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
Topics: Betacoronavirus; Cladribine; Coronavirus Infections; COVID-19; Humans; Lymphopenia; Multiple Sclerosis; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Normal antibody response after COVID-19 during treatment with cladribine.
Topics: Antibodies, Viral; Antibody Formation; Cladribine; COVID-19; COVID-19 Drug Treatment; Female; Humans; Immunosuppressive Agents; Multiple Sclerosis; SARS-CoV-2 | 2020 |
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets.
Topics: Cladribine; COVID-19; COVID-19 Drug Treatment; Humans; Immunosuppressive Agents; Multiple Sclerosis; SARS-CoV-2; Tablets | 2020 |
Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS.
Topics: Adult; B-Lymphocyte Subsets; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Outcome Assessment, Health Care; T-Lymphocyte Subsets; Young Adult | 2020 |
A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment.
Topics: Adenosine Deaminase; Adult; Cladribine; Cytokines; Female; Humans; Immunosuppressive Agents; Inflammation; Leukocyte Count; Male; Multiple Sclerosis; Polymorphism, Single Nucleotide | 2020 |
COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2 | 2021 |
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
Topics: Cladribine; Europe; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Tablets | 2020 |
Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis.
Topics: Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2021 |
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
Topics: Cladribine; COVID-19; Humans; Multiple Sclerosis; Risk Factors; SARS-CoV-2; Vaccination | 2021 |
Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Topics: Adult; Cladribine; Disease Progression; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Retrospective Studies | 2021 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update.
Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Multiple Sclerosis; SARS-CoV-2; Tablets | 2021 |
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
Topics: Adult; Aged; Cladribine; Cohort Studies; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Prospective Studies; Skin; Skin Diseases | 2021 |
A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
Topics: Alemtuzumab; Cladribine; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Retrospective Studies | 2021 |
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2022 |
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.
Topics: Antibodies, Monoclonal, Humanized; Cladribine; COVID-19; COVID-19 Vaccines; Humans; Multiple Sclerosis; SARS-CoV-2 | 2021 |
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).
Topics: Alemtuzumab; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2021 |
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Topics: Cladribine; Glomerulonephritis; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local | 2021 |
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; SARS-CoV-2 | 2021 |
Cladribine - an old newcomer for pulsed immune reconstitution in MS.
Topics: Cladribine; Drug Approval; Europe; Humans; Immunologic Factors; Multiple Sclerosis | 2017 |
Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
Topics: Atrophy; Brain; Cladribine; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2018 |
Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.
Topics: Atrophy; Brain; Cladribine; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2018 |
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
Topics: Administration, Oral; Adult; Alemtuzumab; Apoptosis; B-Lymphocyte Subsets; Cladribine; Cross-Sectional Studies; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Lymph Nodes; Lymphopenia; Male; Multiple Sclerosis; RNA, Messenger; Treatment Outcome | 2018 |
Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Young Adult | 2018 |
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
Topics: Adult; Aged; Cladribine; England; Female; Follow-Up Studies; Guidelines as Topic; Humans; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis; National Health Programs; Off-Label Use; Outcome Assessment, Health Care; Precision Medicine; Young Adult | 2019 |
Should our treatment target in MS include the intrathecal plasma cell response?
Topics: Cladribine; Humans; Immunoglobulin G; Multiple Sclerosis; Oligoclonal Bands; Plasma Cells | 2019 |
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Topics: Alemtuzumab; Cladribine; Crotonates; Decision Support Techniques; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Recurrence; Risk Assessment; Toluidines | 2019 |
Two New Drugs Approved for Multiple Sclerosis.
Topics: Azetidines; Benzyl Compounds; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis | 2019 |
2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.
Topics: Apoptosis; Caspase 3; Caspase 9; Cell Differentiation; Cells, Cultured; Cladribine; Dendritic Cells; DNA Damage; Humans; Immunosuppressive Agents; Leukemia, Hairy Cell; Membrane Potential, Mitochondrial; Monocytes; Multiple Sclerosis; Tumor Suppressor Protein p53 | 2013 |
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Topics: Adult; Analysis of Variance; Antigens, CD; B-Lymphocytes; Cladribine; Dendritic Cells; Female; Flow Cytometry; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; T-Lymphocytes | 2013 |
New treatments for multiple sclerosis: at what long-term risk?
Topics: Cladribine; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis | 2014 |
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
Topics: Adult; CD4 Antigens; CD8 Antigens; Cell Movement; Cladribine; Flow Cytometry; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Lipopolysaccharide Receptors; Monocytes; Multiple Sclerosis; Phytohemagglutinins; T-Lymphocytes | 2009 |
The future of multiple sclerosis therapy.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Injections, Intravenous; Injections, Subcutaneous; Interferon-beta; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
[Multiple sclerosis, the therapeutic arsenal of today and tomorrow].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Causality; Cladribine; Disabled Persons; Fingolimod Hydrochloride; Forecasting; France; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Research; Sphingosine; Vaccination; Vaccines, DNA | 2009 |
New drugs may improve, complicate treatment for multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2010 |
[Emerging treatments for multiple sclerosis].
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Prognosis; Propylene Glycols; Sphingosine | 2010 |
Update on emerging therapies for multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Multiple Sclerosis; Neurology; Propylene Glycols; Sphingosine; Treatment Outcome | 2010 |
Multiple Sclerosis: The Big Questions- The MS Forum Workshop.
Topics: Canada; Cladribine; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Nervous System Diseases; Neurology; Societies, Medical | 2011 |
American academy of neurology annual meeting.
Topics: Academies and Institutes; Administration, Oral; Canada; Cladribine; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Nervous System Diseases; Neurology | 2011 |
Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
Topics: Cladribine; Clinical Trials as Topic; Device Approval; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2011 |
[A plan for risk management in the treatment of multiple sclerosis with movectro (cladribine tablets)].
Topics: Cladribine; Contraindications; Drug Overdose; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Risk Management; Russia; Tablets | 2011 |
Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
Topics: Apoptosis; Cells, Cultured; Cladribine; Cytokines; Deoxycytidine Kinase; Enzyme Activation; Humans; Immunomodulation; Immunosuppressive Agents; Multiple Sclerosis; T-Lymphocytes | 2011 |
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |
Histological examination of the extrabulbar segment of the optic nerve in experimental animals after administration of Cladribine.
Topics: Animals; Cladribine; Dose-Response Relationship, Drug; Leukemia, Hairy Cell; Multiple Sclerosis; Optic Nerve; Optic Nerve Diseases; Rabbits | 2002 |
Influence of the new medicine--2-CDA (Cladribine) on the ultrastructure of the extrabulbar segment of the optic nerve in rabbits of New Zealand breed.
Topics: Animals; Cladribine; Dose-Response Relationship, Drug; Multiple Sclerosis; Optic Nerve; Optic Nerve Diseases; Rabbits | 2002 |
Histological examination of the retinal ganglion layer in rabbits after experimental administration of the new immunosuppressive medicine--Cladribine.
Topics: Animals; Cladribine; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Leukemia, Hairy Cell; Multiple Sclerosis; Rabbits; Reference Values; Retinal Degeneration; Retinal Ganglion Cells | 2002 |
Histological examination of the lacrimal gland after experimental administration of Cladribine.
Topics: Animals; Cladribine; Dose-Response Relationship, Drug; Humans; Lacrimal Apparatus; Lacrimal Apparatus Diseases; Leukemia, Hairy Cell; Multiple Sclerosis; Rabbits | 2002 |
Characterisation of an inclusion complex between cladribine and 2-hydroxypropyl-beta-cyclodextrin.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Oral; beta-Cyclodextrins; Calorimetry, Differential Scanning; Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Spectrum Analysis | 2008 |
Cladribine treatment of multiple sclerosis.
Topics: Cladribine; Humans; Multiple Sclerosis; Research Design | 1994 |
Cladribine treatment of multiple sclerosis.
Topics: Cladribine; Humans; Multiple Sclerosis | 1994 |
Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients.
Topics: Adult; Aged; Blood Cell Count; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis | 1995 |
A comparison of two neurologic scoring instruments for multiple sclerosis.
Topics: Adult; Chronic Disease; Cladribine; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Neurologic Examination | 1996 |
Cladribine treatment of a patient with hairy cell leukemia and concomitant multiple sclerosis.
Topics: Antineoplastic Agents; Cladribine; Disease Progression; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Multiple Sclerosis | 1999 |